Abstract
The search for a biomarker for Parkinson's disease (PD) has led to a surge in literature describing peripheral α-synuclein (aSyn) in both biofluids and biopsy/autopsy tissues. Despite encouraging results, attempts to capitalize on this promise have fallen woefully short. The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for PD. S4 will evaluate aSyn in multiple tissues and biofluids within the same subject and across the disease spectrum to identify the optimal biomarker source and provide vital information on the evolution of peripheral aSyn throughout the disease. Additionally, S4 will correlate the systemic aSyn profile with an objective measure of nigrostriatal dopaminergic function furthering our understanding of the pathophysiological progression of PD.
Author supplied keywords
Cite
CITATION STYLE
Visanji, N. P., Mollenhauer, B., Beach, T. G., Adler, C. H., Coffey, C. S., Kopil, C. M., … Jennings, D. (2017). The Systemic Synuclein Sampling Study: Toward a biomarker for Parkinson’s disease. Biomarkers in Medicine, 11(4), 359–368. https://doi.org/10.2217/bmm-2016-0366
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.